0
Deep & Emerging Tech·August 17, 2026·1 min read

Fidji Simo says she believes AI can 'cure all diseases,' agreeing with Anthropic CEO Dario Amodei

Share

When operators in both AI and biotech talk about “curing all diseases,” the real constraint they name is data infrastructure, not algorithms. Health orgs and biotechs that can standardize, de-identify, and govern longitudinal data at scale are quietly setting themselves up as the scarce input to whatever models come next.

Deep & Emerging Tech

Sources: Crusoe is in IPO talks with at least four Wall Street banks, including JPMorgan, which is advising on its $3B pre-IPO fundraise set to value it at $35B

A $35B pre‑IPO valuation on a data‑center‑plus‑power play like Crusoe is a bet that energy‑integrated compute is a durable profit pool, not a sidecar to cloud. If you’re planning AI capacity, you now have to price against specialized infra players who control both megawatts and racks—not just hyperscalers.

Deep & Emerging Tech

BNPL lenders like Flex, Zip, and Affirm are now pitching loans for basic household needs; Americans spent $160B through pay-later loans in 2025, up 2x from 2023

BNPL doubling to $160B in two years and drifting into basic household spend is a macro‑risk story as much as a fintech growth story—household liquidity is being propped up by opaque, non‑bank credit. Consumer‑facing operators should expect more regulatory guardrails and higher delinquency volatility in their customer base, especially at the lower end of the income spectrum.